Repare Therapeutics Inc. (NASDAQ:RPTX) Stock Holdings Increased by Tower Research Capital LLC TRC

Tower Research Capital LLC TRC boosted its position in Repare Therapeutics Inc. (NASDAQ:RPTX) by 533.2% in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 11,316 shares of the company’s stock after buying an additional 9,529 shares during the quarter. Tower Research Capital LLC TRC’s holdings in Repare Therapeutics were worth $111,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also recently bought and sold shares of RPTX. Deutsche Bank AG bought a new stake in Repare Therapeutics in the fourth quarter valued at about $40,000. UBS Group AG boosted its stake in Repare Therapeutics by 26.3% in the third quarter. UBS Group AG now owns 3,551 shares of the company’s stock valued at $43,000 after acquiring an additional 739 shares during the period. Wells Fargo & Company MN boosted its stake in Repare Therapeutics by 185.8% in the fourth quarter. Wells Fargo & Company MN now owns 3,041 shares of the company’s stock valued at $45,000 after acquiring an additional 1,977 shares during the period. Lazard Asset Management LLC acquired a new position in Repare Therapeutics in the fourth quarter valued at approximately $114,000. Finally, Compagnie Lombard Odier SCmA acquired a new position in Repare Therapeutics in the first quarter valued at approximately $140,000. 85.09% of the stock is owned by institutional investors.

Repare Therapeutics Trading Down 1.0 %

Shares of NASDAQ RPTX opened at $9.66 on Friday. The stock has a 50 day simple moving average of $10.07 and a 200-day simple moving average of $10.20. The company has a market cap of $406.59 million, a PE ratio of -64.40 and a beta of 0.05. Repare Therapeutics Inc. has a 12-month low of $8.02 and a 12-month high of $18.68.

Analyst Ratings Changes

A number of equities analysts have commented on the company. Stifel Nicolaus upgraded Repare Therapeutics from a “hold” rating to a “buy” rating and lifted their target price for the company from $11.00 to $16.00 in a research note on Friday, June 9th. HC Wainwright decreased their target price on Repare Therapeutics from $26.00 to $25.00 and set a “buy” rating for the company in a research note on Thursday, August 17th.

Repare Therapeutics Profile

Repare Therapeutics Inc, a clinical-stage precision oncology company, engages in the discovery and development of therapeutics by using its synthetic lethality approach in Canada and the United States. It uses its SNIPRx, a proprietary, genome-wide, and CRISPR-enabled platform, to discover, validate, and build a pipeline of SL-based therapeutics that focuses on genomic instability, including DNA damage repair.